Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Imagyn Medical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Imagyn Medical Technologies: Consolidation and cost-cutting effort announced Jan. 21 includes plans to close the firm's Laguna Niguel, California plant and move its endoscope manufacturing facility to Costa Mesa. Imagyn will lay off about 120 people as part of the consolidation, which "along with other cost cutting measures" will cut expenditures by about $18 mil. a year, the firm estimates. The move follows the Oct. 1 acquisition of Imagyn Medical by Urohealth Systems ("The Gray Sheet" July 21, 1997, I&W-1) and represents "part of Imagyn's ongoing plan to integrate acquired companies into its mainstream businesses, thereby eliminating redundant staffing and facilities," Imagyn explains. Separately, Imagyn has inked a definitive agreement with International Isotopes that gives Imagyn exclusive worldwide marketing rights to radioactive seeds for treatment of prostate cancer. A March 510(k) submission is anticipated for an initial iodine 125 brachytherapy seed product...

You may also be interested in...



Celltrion Invests $450m Into Incheon Manufacturing Site

Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market

Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel